Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:45:31.939Z.
Calculation as of: 2026-10-06T19:45:31.939Z.
Quote observation: 2026-10-06T19:45:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 017b786e338061c10a4665063360519c0b30ae95494f37f63af909a19a8b52dc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2018-03-29.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
PRICE/FCF RATIO AVG TTM
N/A
PRICE/FCF RATIO AVG 3Y
N/A
PRICE/FCF RATIO AVG 5Y
N/A
PRICE/FCF RATIO AVG 10Y
N/A
PRICE/FCF RATIO AVG 15Y
N/A
PRICE/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$58.85M
Price/FCF Ratio
N/A
TTM Avg
2.61
3Y Avg
2.61
5Y Avg
2.61
Market Cap
$58.80M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$57.33M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adicet Bio, Inc. (ACET) | $58.43M | N/A | N/A | N/A | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $58.85M | N/A | 2.61 | 2.61 | 2.61 |
| PDS Biotechnology Corporation (PDSB)vs › | $58.80M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.54M | N/A | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.22M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.98M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $59.76M | N/A | N/A | N/A | N/A |
| Talphera, Inc. (TLPH)vs › | $57.61M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.33M | N/A | N/A | N/A | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.98M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/FCF RATIO |
|---|---|
| 2018-03-29 | 57.50 |
| 2018-03-28 | 63.38 |
| 2018-03-27 | 67.46 |
| 2018-03-26 | 65.72 |
| 2018-03-23 | 70.70 |
| 2018-03-22 | 79.11 |
| 2018-03-21 | 88.23 |
| 2018-03-20 | 89.31 |
| 2018-03-19 | 90.45 |
| 2018-03-16 | 89.73 |
| 2018-03-15 | 89.55 |
| 2018-03-14 | 90.51 |
| 2018-03-13 | 92.73 |
| 2018-03-12 | 95.43 |
| 2018-03-09 | 95.43 |
| 2018-03-08 | 97.11 |
| 2018-03-07 | 102.09 |
| 2018-03-06 | 103.24 |
| 2018-03-05 | 105.82 |
| 2018-03-02 | 106.42 |
| 2018-03-01 | 110.26 |
| 2018-02-28 | 117.04 |
| 2018-02-27 | 118.54 |
| 2018-02-26 | 123.64 |
| 2018-02-23 | 125.14 |
| 2018-02-22 | 117.94 |
| 2018-02-21 | 118.18 |
| 2018-02-20 | 117.04 |
| 2018-02-16 | 112.60 |
| 2018-02-15 | 109.36 |
| 2018-02-14 | 108.58 |
| 2018-02-13 | 109.54 |
| 2018-02-12 | 108.64 |
| 2018-02-09 | 102.03 |
| 2018-02-08 | 99.03 |
| 2018-02-07 | 97.35 |
| 2018-02-06 | 96.51 |
| 2018-02-05 | 101.67 |
| 2018-02-02 | 102.27 |
| 2018-02-01 | 100.53 |
| 2018-01-31 | 97.35 |
| 2018-01-30 | 94.47 |
| 2018-01-29 | 97.41 |
| 2018-01-26 | 101.31 |
